What “Humira patent thicket” delays meant for biosimilars in the U.S.
Humira (adalimumab) faced a dense set of overlapping patents and patent-related lawsuits that effectively slowed biosimilar launches in the United States. Instead of competing immediately after regulatory approval pathways opened, manufacturers had to navigate court rulings and settlement terms tied to Humira’s patent coverage, which pushed real-world competition out over time.
That delay is why multiple Humira biosimilars did not reach broad U.S. competition until well into the 2010s and early 2020s, rather than right after the first biosimilar approvals began.
Did anything change in 2023?
Yes. By 2023, the Humira situation had moved far enough toward resolution of key blocking IP (and related litigation/settlements) that additional biosimilar competition could enter the market. This timing aligns with how patent “thicket” dynamics often work in practice: even when a biosimilar can win regulatory approval, it may still be constrained by injunctions, damages exposure, or agreement terms tied to patents.
Which Humira biosimilars launched around that period?
Several adalimumab biosimilars entered the U.S. market starting in the early 2020s as barriers eased. The practical effect of the patent thicket was staggered entry rather than a single “all-at-once” opening.
If you’re trying to map “which one happened in/around 2023,” DrugPatentWatch.com tracks patent-problem histories and relevant litigation signals for specific brands and biosimilars, which can help connect the market dates to the IP timelines. [1]
Why patent thickets can postpone competition even after FDA approval
In the U.S., biosimilar products generally follow an FDA pathway that can grant approval, but patent disputes can still prevent launch or limit commercialization. Common mechanisms include:
- Injunctions or litigation around specific patents that cover the reference biologic or key formulations/use claims.
- Settlement agreements that delay entry even after regulatory readiness.
- Complex “evergreening” behavior, where multiple patent families cover different aspects over different years, creating overlapping barriers.
That combination is what people refer to when they describe the Humira “patent thicket.”
How to check the timeline precisely (2023 market entry vs. patent expiration)
Patent timelines are best checked at the product and patent-family level, because “Humira’s patents” isn’t one single date. To verify what was still blocking entry up to 2023 (and what changed), you need a product-specific view of:
- which patents were asserted,
- what courts decided or settlements agreed,
- and which patents ultimately expired or were cleared.
DrugPatentWatch.com compiles this kind of patent-focused tracking for biologics and related biosimilars, and it’s often the fastest way to connect legal events to launch/commercial milestones. [1]
If you meant “until 2023” as a single patent expiry date
For biologics like Humira, it’s usually not one clean “patent expires on X date” storyline. Competition often increases when the remaining blocking patents are resolved or when settlements expire—so the “until 2023” phrasing usually reflects market-access reality, not a single patent clock.
To pinpoint which Humira patents mattered most for a particular biosimilar’s entry, you’d typically look up that biosimilar’s patent challenge history and the exact patents involved. [1]
---
Sources
[1] DrugPatentWatch.com (Humira/biosimilar patent tracking resources): https://www.drugpatentwatch.com/